OncoMatch/Clinical Trials/NCT06553352

Zanubrutinib in Combination With Obinutuzumab (ZO) for Newly Diagnosed Follicular Lymphoma

Is NCT06553352 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Zanubrutinib combined with Obinutuzumab for follicular lymphoma.

Phase 2RecruitingThe First Affiliated Hospital of Xiamen UniversityNCT06553352Data as of May 2026

Treatment: Zanubrutinib combined with Obinutuzumab — To evaluate the efficacy and side effects of Zanubrutinib combined with Obinutuzumab (ZO) in the treatment of newly diagnosed follicular lymphoma.

Check if I qualify

Extracted eligibility criteria

Cancer type

Non-Hodgkin Lymphoma

Disease stage

Required: Stage II, III, IV

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Lab requirements

Kidney function

serum Cr ≤ 2.0 × ULN (unless due to lymphoma)

Liver function

serum bilirubin ≤ 2.0 × ULN , serum ALT and AST ≤ 2.5 × ULN (unless due to lymphoma)

Normal major organ function: liver function serum bilirubin ≤ 2.0 × ULN , serum ALT and AST ≤ 2.5 × ULN, renal function: serum Cr ≤ 2.0 × ULN; (unless due to lymphoma)

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify